Physician profile
Mark Firestone
NPI 1558349563
$133,292.38
in general payments reported to CMS, 2019-2025
32 companies · $62K in 2025
The $62K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,454 · 2020: $544 · 2021: $17K · 2022: $4,135 · 2023: $26K · 2024: $22K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $84K · Travel and Lodging: $9,372 · Honoraria: $8,370 · Food and Beverage: $7,787 · Consulting Fee: $175 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $84,240.00 |
| Travel and Lodging | $9,371.70 |
| Honoraria | $8,370.00 |
| Food and Beverage | $7,786.72 |
| Consulting Fee | $175.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $108,400.21 | 2021-2025 | |
| Abbvie INC. | $20,827.96 | 2019-2024 | |
| Exeltis, USA INC. | $807.57 | 2019-2025 | Slynd |
| Astellas Pharma US INC | $561.64 | 2022-2025 | Veozah |
| Amgen INC. | $382.24 | 2019-2025 | Prolia |
| Therapeuticsmd, INC. | $276.87 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $261.50 | 2019-2025 | |
| Exact Sciences Corporation | $204.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Vertical Pharmaceuticals, LLC | $200.51 | 2019 | |
| Allergan, INC. | $187.68 | 2019-2020 | |
| Coopersurgical, INC. | $175.35 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Millicent US INC | $160.12 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Evofem Biosciences, INC. | $137.52 | 2021-2025 | Phexxi, Solosec, Phexx |
| Radius Health, INC. | $102.24 | 2020-2022 | |
| Organon LLC | $93.69 | 2021-2024 | Nexplanon |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $89.29 | 2021-2024 | |
| Avion Pharmaceuticals | $69.91 | 2020-2022 | |
| Hologic Sales and Service, LLC | $54.95 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Duchesnay USA Incorporated | $54.43 | 2019 | |
| Merck Sharp & Dohme LLC | $48.85 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $46.80 | 2023-2024 | Myfembree |
| Amag Pharmaceuticals, INC. | $43.99 | 2019 | |
| Shield Therapeutics INC | $38.00 | 2023 | Accrufer |
| Ascend Therapeutics US, LLC | $19.10 | 2024 | |
| Biogen, INC. | $18.66 | 2025 | Zurzuvae |
| Lupin INC. | $16.43 | 2021 | |
| Zyla Life Sciences, INC. | $12.26 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Firestone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.